Difference between revisions of "Cabozantinib (Cometriq)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
Line 20: Line 20:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]].
+
===[[Hepatocellular carcinoma]]===
−
*4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm FDA approved] (as Cabometyx) for the treatment of advanced [[Renal_cell_carcinoma|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]].
+
*1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''(new disease entity)''
−
*12/19/2017: Granted FDA regular approval for treatment of patients with advanced [[Renal_cell_carcinoma|renal cell carcinoma (RCC)]].
+
===[[Thyroid_cancer#Medullary_thyroid_cancer | Medullary thyroid cancer]]===
 +
*11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm Initial approval] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]].
 +
===[[Renal cell carcinoma]]===
 +
*4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm Approved] (as Cabometyx) for the treatment of advanced [[Renal_cell_carcinoma|renal cell carcinoma]] in patients who have received prior [[:Category:VEGFR_inhibitors|anti-angiogenic therapy]]. ''(new disease entity)''
 +
*12/19/2017: Granted FDA regular approval for treatment of patients with advanced [[Renal_cell_carcinoma|renal cell carcinoma (RCC)]]. ''(converted to regular approval; no longer requires prior treatment)''
  
 
==Also known as==
 
==Also known as==

Revision as of 22:16, 31 January 2019

General information

Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Hepatocellular carcinoma

  • 1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (new disease entity)

Medullary thyroid cancer

Renal cell carcinoma

Also known as

  • Code names: XL184, XL-184
  • Brand names: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.

References

  1. ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
  2. ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
  3. ↑ Cometriq manufacturer's website
  4. ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
  5. ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
  6. ↑ Cabometyx manufacturer's website
  7. ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
  8. ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Cabozantinib_(Cometriq)&oldid=35292"